# Sinocelltech Ltd. clinical trials: 82 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 82 trials with Sinocelltech Ltd. as lead sponsor, 28 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sinocelltech Ltd.: 82 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sinocelltech-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 82
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 82, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07903831 | Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B | Sinocelltech Ltd. | Phase 1 | Not yet recruiting | Hepatitis B | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903831) |
| September 29, 2026 | NCT07847697 | A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10 | Sinocelltech Ltd. | Phase 1 | Not yet recruiting | Healthy Participants | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847697) |
| September 14, 2026 | NCT07819188 | SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | NHL - Non-Hodgkin's Lymphoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819188) |
| June 24, 2026 | NCT07665970 | SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | Advanced Malignant Solid Tumors | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665970) |
| June 23, 2026 | NCT07662395 | SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer | Sinocelltech Ltd. | Phase 2/3 | Recruiting | Double Blind | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662395) |
| May 27, 2026 | NCT07609251 | A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung... | Sinocelltech Ltd. | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609251) |
| May 18, 2026 | NCT07594028 | Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | Advanced Malignant Solid Tumor | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594028) |
| May 6, 2026 | NCT07570823 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or... | Sinocelltech Ltd. | Phase 3 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570823) |
| May 1, 2026 | NCT07562022 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular... | Sinocelltech Ltd. | Phase 3 | Recruiting | Follicular Lymphoma (FL) | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07562022) |
| April 20, 2026 | NCT07538154 | A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | Systemic Lupus Erythematosus (SLE) | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538154) |
| February 27, 2026 | NCT07437404 | Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. | Sinocelltech Ltd. | Phase 3 | Recruiting | Haemophilia A | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07437404) |
| February 5, 2026 | NCT07388602 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With... | Sinocelltech Ltd. | Phase 3 | Recruiting | Amyloidosis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388602) |
| January 23, 2026 | NCT07362459 | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | Sinocelltech Ltd. | Phase 3 | Recruiting | Non-Small Cell Lung Carcinoma (NSCLC) | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362459) |
| December 22, 2025 | NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With... | Sinocelltech Ltd. | Phase 3 | Recruiting | Multiple Myeloma (MM) | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297329) |
| November 24, 2025 | NCT07244510 | Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa | Sinocelltech Ltd. | Phase 2 | Recruiting | Hidradenitis Suppurativa (HS) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07244510) |
| July 22, 2025 | NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | Advanced Malignant Solid Tumor | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07077252) |
| July 3, 2025 | NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | Sinocelltech Ltd. | Phase 1/2 | Recruiting | Advanced Malignant Solid Tumor | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07050641) |
| February 21, 2025 | NCT06841042 | A Study of SCTB35 in Patients with Systemic Lupus Erythematosus | Sinocelltech Ltd. | Phase 1/2 | Recruiting | System Lupus Erythematosus | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06841042) |
| January 30, 2025 | NCT06801509 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | Herpes Zoster | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06801509) |
| January 14, 2025 | NCT06774664 | A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | IgA Nephropathy | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06774664) |
| January 10, 2025 | NCT06769984 | A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | TED | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06769984) |
| January 1, 2025 | NCT06754605 | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine | Sinocelltech Ltd. | Phase 1/2 | Recruiting | Respiratory Syncytial Virus | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06754605) |
| November 4, 2024 | NCT06672536 | Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD | Sinocelltech Ltd. | Phase 1/2 | Recruiting | nAMD | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06672536) |
| September 19, 2024 | NCT06600022 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. | Sinocelltech Ltd. | Phase 1/2 | Recruiting | Advanced Malignant Solid Tumours | 441 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06600022) |
| March 19, 2024 | NCT06318884 | A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma | Sinocelltech Ltd. | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, B-cell | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06318884) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 1/2 | 20 |
| Phase 2 | 20 |
| Phase 2/3 | 5 |
| Phase 3 | 19 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 42 |
| Not yet recruiting | 14 |
| Recruiting | 14 |
| Completed | 6 |
| Withdrawn | 3 |
| Terminated | 2 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 21 |
| Hemophilia A | 6 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Squamous Cell | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Neoplasms | 3 |
| Colorectal Neoplasms | 3 |
| Lymphoma, Non-Hodgkin | 2 |
| Head and Neck Neoplasms | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Lymphoma, B-Cell | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
| Glomerulonephritis, IGA | 1 |
| Axial Spondyloarthritis | 1 |
| Papillomavirus Infections | 1 |
| Hepatitis B | 1 |
| Hepatitis B, Chronic | 1 |
| Multiple Myeloma | 1 |
| Carcinoma, Hepatocellular | 1 |
| Lymphoma, Follicular | 1 |
| Recurrence | 1 |
| Hematologic Neoplasms | 1 |
| Psoriasis | 1 |
| Lymphoma | 1 |
| Amyloidosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B cleaning and waste management companies in the United States](https://specstream.ai/data/businesses/b2b-cleaning-and-waste-management-companies/united-states)
- [Plumbers in the United States](https://specstream.ai/data/businesses/plumbers/united-states)
- [Filipino restaurants in the United States](https://specstream.ai/data/businesses/filipino-restaurants/united-states)
- [Animation studios in the United States](https://specstream.ai/data/businesses/animation-studios/united-states)
- [Patio cover companies in the United States](https://specstream.ai/data/businesses/patio-cover-companies/united-states)
- [Energy companies in the United States](https://specstream.ai/data/businesses/energy-companies/united-states)
